Completed PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT02286778

Eradication of Malignant Carcinoma in the Breast Tissue

The Eradication of Malignant Carcinoma in the Breast Tissue Using an ATP (Adenosine-5'-Triphosphate) Inhibitor

Sponsor: Optimal Health Research

Updated 7 times since 2017 Last updated: Aug 2, 2017 Started: Feb 29, 2016 Primary completion: Jan 31, 2017 Completion: Aug 1, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Optimal Health Research and has accumulated 7 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Aug 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

Status: Active Not Recruiting → Completed

▶ Show 2 earlier versions

Feb 2017 — Aug 2017 [monthly]

Active Not Recruiting PHASE2_PHASE3

Status: Enrolling By Invitation → Active Not Recruiting
Jan 2017 — Feb 2017 [monthly]

Enrolling By Invitation PHASE2_PHASE3

First recorded

Feb 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Optimal Health Research

Data source: Optimal Health Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.